Journals / Turkish Journal of Internal Medicine / 2026 / Volume: 4 Special Issue

Evaluation of Patients Performed with Saline Infusion Test with a Pre-Diagnosis of Primary Hyperaldosteronism

Coşkun Ateş(BURSA ULUDAG UNIVERSITY)0000-0003-4565-9848
Gül Ada(BURSA ULUDAG UNIVERSITY)0000-0002-0449-2482
Ensar Aydemir(Bursa Uludağ Üniversitesi)0000-0003-4300-2965
Erhan Hocaoğlu(BURSA ULUDAG UNIVERSITY)0000-0002-6299-9513
Özen Öz Gül(BURSA ULUDAG UNIVERSITY)0000-0002-1332-4165
Soner Cander(BURSA ULUDAG UNIVERSITY)0000-0001-6303-7896
Canan Ersoy(BURSA ULUDAG UNIVERSITY)0000-0002-4672-7681
Erdinç Ertürk(BURSA ULUDAG UNIVERSITY)0000-0003-2399-6608
Pages
—
Publication Date
2022-04-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Its use alone was not sufficient in the differential diagnosis of aldosterone-synthesizing adenoma and idiopathic hyperaldosteronism.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Primary hyperaldosteronism (PHA) is a primarily treatable cause of arterial hypertension characterized by low plasma renin and high aldosterone levels.
📊
Key Findings & Data:The prevalence of secondary hypertension as a common endocrine cause is 5-13%.
💡
Conclusion & Impact:Its use alone was not sufficient in the differential diagnosis of aldosterone-synthesizing adenoma and idiopathic hyperaldosteronism.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:primary hyperaldosteronism · saline infusion test · essential hypertension

Abstract

Background: Primary hyperaldosteronism (PHA) is a primarily treatable cause of arterial hypertension characterized by low plasma renin and high aldosterone levels. The prevalence of secondary hypertension as a common endocrine cause is 5-13%. The plasma aldosterone/renin ratio (ARR) is the best available method for PHA screening. One or more confirmatory tests may be required to confirm or exclude patients' diagnoses. One frequently used confirmatory test is the saline infusion test (SİT). We aimed to screen the patients who underwent SİT with the preliminary diagnosis of PHA and to compare the results of the patients diagnosed with essential hypertension (EH) and PHA. Material and Methods: Seventy-seven patients with a history of drug-resistant hypertension or unexplained spontaneous or diuretic-induced hypokalemia or adrenal incidentaloma, or a family history of early-onset hypertension or cerebrovascular accident at a young age ( 0.05). Basal plasma aldosterone (p 0.05). The mean sodium value was significantly higher than the IHA (p <0.05). Conclusion: Our study determined that the saline infusion test could be used to confirm the diagnosis of primary hyperaldosteronism. Its use alone was not sufficient in the differential diagnosis of aldosterone-synthesizing adenoma and idiopathic hyperaldosteronism.

🔖

Cite This Article

Ateş, C., Ada, G., Sarıdaş, F. M., Aydemir, E., Hocaoğlu, E., Gül, Ö. Ö., Cander, S., Ersoy, C., Ertürk, E. (2022). Evaluation of Patients Performed with Saline Infusion Test with a Pre-Diagnosis of Primary Hyperaldosteronism. Turkish Journal of Internal Medicine, Volume: 4 Special Issue. https://doi.org/10.46310/tjim.1072050

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Rossi GP. Primary aldosteronism: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Dec 3;74(22):2799-811. doi: 10. 1016/j.jacc.2019.09.057.
  2. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006 Dec 5;48(11):2293-300. doi: 10.1016/j.jacc.2006.07.059.
  3. Conn JW. Aldosterone in clinical medicine; past, present, and future. AMA Arch Intern Med. 1956 Feb;97(2):135-44. doi: 10.1001/archinte.1956.00250200011001.
  4. Catena C, Colussi G, Sechi LA. Treatment of primary aldosteronism and organ protection. Int J Endocrinol. 2015;2015:597247. doi: 10.1155/2015/597247.
  5. Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, Quinkler M, HanslikG, Lang K, Hahner S, Allolio B, Meisinger C, Holle R, Beuschlein F, Bidlingmaier M, Endres S. Observational study mortality in treated primary aldosteronism: the German Conn’s registry. Hypertension. 2012 Sep;60(3):618- 24. doi: 10.1161/HYPERTENSIONAHA.112.197111.
  6. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916. doi: 10.1210/ jc.2015-4061.
  7. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, V Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008 Sep;93(9):3266-81. doi: 10.1210/ jc.2008-0104.
  8. Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens. 2006 Apr;24(4):737-45. doi: 10.1097/01. hjh.0000217857.20241.0f.
  9. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Semplicini A, Agabiti-Rosei E, Pessina AC, Mantero F; PAPY Study Investigators. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone- producing adenoma. J Hypertens. 2007 Jul;25(7):1433-42. doi: 10.1097/HJH.0b013e328126856e.
  10. Ahmed AH, Gordon RD, Taylor PJ, Ward G, Pimenta E, Stowasser M. Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men? J Clin Endocrinol Metab. 2011 Feb;96(2):E340-6. doi: 10.1210/jc.2010-1355.
  11. Rossi GP. A comprehensive review of the clinical aspects of primary aldosteronism. Nat Rev Endocrinol. 2011 May 24;7(8):485-95. doi: 10.1038/nrendo.2011.76.
  12. Alam S, Kandasamy D, Goyal A, Vishnubhatla S, Singh S, Karthikeyan G, Khadgawat R. High prevalence and a long delay in the diagnosis of primary aldosteronism among patients with young-onset hypertension. Clin Endocrinol (Oxf). 2021 Jun;94(6):895-903. doi: 10.1111/cen.14409.
  13. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctableforms,incentersfromfivecontinents.JClinEndocrinol Metab. 2004 Mar;89(3):1045-50. doi: 10.1210/jc.2003-031337.
  14. Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, Quinkler M, HanslikG, Lang K, Hahner S, Allolio B, Meisinger C, Holle R, Beuschlein F, Bidlingmaier M, Endres S. Observational study mortality in treated primary aldosteronism: the German Conn’s registry. Hypertension. 2012 Sep;60(3):618- 24. doi: 10.1161/HYPERTENSIONAHA.112.197111.